View Article

Abstract

Chromatographic analytical procedures are central to pharmaceutical quality control, development and stability assessment. High-performance liquid chromatography (HPLC) and high-performance thin-layer chromatography (HPTLC) are versatile platforms, but their performance is governed by multiple interacting experimental variables. Conventional one-factor-at-a-time development may therefore be inefficient for complex separations because it provides limited information about interactions between factors. Chemometric-assisted development, particularly when integrated with design of experiments (DoE), provides a structured framework for screening influential variables, modelling factor–response relationships and optimizing multiple analytical responses. This review discusses the role of chemometrics in HPLC and HPTLC method development, with emphasis on analytical target profile (ATP), risk assessment, critical method parameters, response selection, screening designs, response-surface methodology, regression modelling, analysis of variance, desirability-based multi-response optimization and confirmation experiments. Examples from published pharmaceutical analytical studies illustrate the practical application of DoE-supported optimization in both column and planar chromatography. The review also considers analytical procedure validation and the relationship of chemometric development with ICH Q14 and ICH Q2(R2). Advantages, limitations, practical challenges and future directions, including data-driven and machine-learning-assisted approaches, are discussed.

Keywords

Chemometrics; HPLC; HPTLC; Design of Experiments; Analytical Quality by Design; Method Optimization

Introduction

× Popup Image

Reliable analytical measurements are essential for pharmaceutical quality assurance because analytical procedures support identity testing, assay, purity and impurity determination, stability assessment and routine quality control. HPLC is among the most broadly applied separation techniques in pharmaceutical analysis, whereas HPTLC provides a planar chromatographic platform suited to rapid analysis, fingerprinting and quantitative densitometry. The performance of either technique depends on the appropriate selection and control of method variables.

Chromatographic development commonly involves selection of the stationary phase, mobi le phase, detection conditions, elution mode, flow rate, temperature and other operating parameters. Because these variables can influence one another, sequential experimentation may fail to reveal important interactions. For example, changes in organic -solvent proportion can alter retention and selectivity, while pH can change analyte ionization and consequently influence retention and separation.

Chemometric approaches provide a structured framework in which several factors can be studied simultaneously and their effects on predefined analytical responses can be quantified.

The objective of this review is to consolidate the role of chemometric and DoE -based approaches in HPLC and HPTLC method optimization, explain their relationship with analytical quality by design(AQbD), and discuss model evaluation, validation, applications, limitations and future directions relevant to pharmaceutical quality assurance.

2. FUNDAMENTALS OF HPLC AND HPTLC

2.1 High-Performance Liquid Chromatography

HPLC separates components according to their differential interactions with a stationary phase and a mobile phase under controlled flow. In reversed -phase HPLC, a non -polar stationary phase such as C18 is commonly combined with an aqueous -organic mobile phase. Analyte physicochemical properties and chromatographic conditions influence retention, selectivity, efficiency and peak shape.

2.2 High-Performance Thin-Layer Chromatography

HPTLC is a planar chromatographic technique performed on precoated plates containing a suitable stationary phase. Samples are applied as controlled spots or bands, the plate is developed with a selected mobile phase and separated components are detected using densitometry or other suitable optical systems. Important observations include Rf, resolution, band shape and detector response. The ability to analyze multiple samples in parallel makes HPTLC useful for screening, identification, fingerprinting and quantitative analysis.

3. CHEMOMETRICS IN CHROMATOGRAPHIC METHOD DEVELOPMENT

Chemometrics is the application of mathematical, statistical and computational methods to obtain useful information from chemical measurements. In chromatographic development, chemometrics can support experimental planning, regression modelling, multivariate interpretation and optimization.

Rather than relying exclusively on trial -and-error experimentation, a planned design can generate information about main effects, interactions and, where appropriate, curvature within the experimental region.

3.1 Chemometric tool Role in analytical development

  1. Design of Experiments: Plans experiments to estimate factor effects efficiently.
  2. Regression modelling: Relates method factors to analytical responses.
  3. ANOVA: Assesses statistical significance and partitions variation.
  4. Response Surface Methodology: Models and visualizes response behaviour in the experimental region.
  5. Desirability function: Combines multiple response goals into an optimization criterion.
  6. PCA / PLS: Supports multivariate exploration or prediction when appropriate to the dataset.

3.2 Chemometric vs. Simple Calculation

Mean, standard deviation or %RSD calculations performed after experimentation are not, by

themselves, chemometric optimization. A chemometric strategy uses structured multivariable

information to build or interrogate a model and then verifies that th e selected conditions provide the intended analytical performance.

 

TABLE 1. COMPARISON OF HPLC AND HPTLC IN CHEMOMETRIC METHOD DEVELOPMENT

Feature

HPLC

HPTLC

Format

Column

Planar plate

Primary migration measure

Retention time

Rf

Typical optimization variables

Mobile phase, pH, flow, temperature, gradient

Solvent composition, saturation, development distance, detection

Typical responses

Resolution, retention, plates, tailing, area

Rf, resolution, area/height, band shape

Major strength

High-resolution quantitative separation

Parallel analysis and fingerprinting

 

4. ANALYTICAL QUALITY BY DESIGN AND ANALYTICAL TARGET PROFILE

AQbD applies quality-by-design principles to analytical procedure development. The Analytical Target Profile (ATP) defines what  the analytical procedure is intended to measure and the required performance characteristics. ICH Q14 provides a science - and risk -based framework for analytical procedure development and lifecycle management, while ICH Q2(R2) addresses validation of analytical procedures.

1. Define the analytical objective and ATP.

2. Identify product, analyte and method knowledge.

3. Perform risk assessment.

4. Identify potential critical method parameters.

5. Select critical analytical responses.

6. Apply DoE for screening and/or optimization.

7. Develop and evaluate the statistical model.

8. Define suitable operating conditions or an appropriate region.

9. Perform confirmation experiments.

10. Validate the finalized analytical procedure and establish an appropriate control strategy.

5. DESIGN OF EXPERIMENTS IN CHROMATOGRAPHIC DEVELOPMENT

DoE investigates multiple factors in a planned and statistically interpretable manner. The choice of design depends on the number and type of factors, development stage, experimental region and information required.

Design Main purpose Typical chromatographic application Two-level factorial Main effects and interactions Small number of factors Fractional factorial Efficient screening Several potential factors Plackett–Burman Factor screening Many factors with limited runs Central Composite Design Quadratic response modelling Optimization of selected quantitative factors Box–Behnken Design Quadratic optimization without extreme combinations Three or more quantitative factors Mixture design Optimization of component proportions Mobile-phase mixtures

 

TABLE 2. COMMON DOE DESIGNS AND THEIR ROLES

Design

Primary use

Typical application

Full factorial

Main effects and interactions

 

Small factor sets

Fractional factorial

Efficient screening

 

Several factors

Plackett–Burman

Factor screening

 

Many potential factors

Central Composite Design

Quadratic response modelling

 

Optimization of quantitative factors

Box–Behnken Design

Quadratic optimization

 

Three or more quantitative factors

Mixture design

Proportion optimization

 

Mobile-phase mixtures

 

6. SELECTION OF FACTORS AND RESPONSES

6.1 Critical Method Parameters

Factors should be selected using prior scientific knowledge, risk assessment, published evidence, preliminary experiments and practical operating limits. The investigated levels should cover a meaningful and scientifically justified region. Overly narrow ranges can conceal important behaviour, whereas unnecessarily broad ranges may generate unsuitable chromatographic conditions.

6.2 HPLC Factors and Responses

  1. Organic modifier proportion Elution strength, retention and selectivity Mobile-phase pH Ionization, retention and selectivity
  2. Flow rate Retention, efficiency and analysis time
  3. Column temperature Viscosity, retention, selectivity and peak shape
  4. Gradient composition/slope Separation and total run time
  5. Column chemistry Selectivity and peak shape
  6. Common HPLC responses include retention time, resolution, theoretical plate count, tailing factor, peak area and precision indicators. Optimization should be based on predefined analytical objectives rather than on a single response in isolation.
    1. HPTLC Factors and Responses
  1. Organic-phase proportion Rf and resolution
  2. Chamber saturation time Rf, development behaviour and reproducibility
  3. Development distance Resolution and analysis time
  4. Detection wavelength Peak response and sensitivity
  5. Application conditions Band shape and precision
  1. CHEMOMETRIC-ASSISTED HPLC OPTIMIZATION

HPLC optimization should begin with a scientifically reasonable chromatographic system. After preliminary selection of column and other conditions, selected high -risk variables can be investigated over a defined experimental region using an appropriate DoE.

7.1 Example Experimental Strategy

For illustration, organic-modifier proportion (X1), mobile -phase pH (X2) and flow rate (X3) may be selected after risk assessment. A Box–Behnken or Central Composite Design can be used to generate planned experimental runs. Resolution (Y1), retention time (Y2) and tailing factor (Y3) can then be measured. Regression models are fitted to describe the relationship between factors and responses, followed by model adequacy assessment and multi-response optimization.

7.2 Multi-Response Optimization

Chromatographic method development usually requires simultaneous control of several responses.

Maximizing resolution alone, for example, may result in an unnecessarily long analysis. A desirability-based approach can combine goals such as maximizing resolution, minimizing analysis time and maintaining peak symmetry within an acceptable range. The predicted optimum should always be subjected to confirmation experiments.

    1. Published HPLC Evidence

DoE-supported HPLC method development has been reported for pharmaceutical analysis. The supplied report highlights an RP-HPLC study of torsemide and eplerenone in which Central Composite Design and response -surface methodology were used for multivariate optimization. Such studies illustrate how planned experimentation can replace extensive trial-and-error adjustment with a model-based development strategy.

  1. CHEMOMETRIC-ASSISTED HPTLC OPTIMIZATION

HPTLC method development can similarly bene fit from DoE because solvent composition, chamber saturation, development distance and detection conditions may jointly affect migration and separation.

The Rf value is particularly important because excessively low or high migration can reduce practical separation quality.

8.1 Published HPTLC Evidence

The supplied report identifies published DoE -supported HPTLC examples involving efinaconazole, retapamulin, and a stability -indicating assay involving roxithromycin and ambroxol hydrochloride.

These examples demonstrate the use of response -surface designs, optimization of chromatographic variables and subsequent method validation.

8.2 HPTLC Optimization Workflow

1. Select a suitable stationary phase and establish an initial solvent system.

2. Identify high-risk chromatographic variables.

3. Select a screening or response-surface design.

4. Perform planned HPTLC experiments.

5. Measure Rf, resolution, response and other predefined attributes.

6. Fit the model and evaluate model adequacy.

7. Select the optimum region using predefined criteria.

8. Perform confirmation experiments.

9. Validate the finalized method.

 

TABLE 3. TYPICAL FACTORS AND RESPONSES

Technique

Factors

Responses

 

HPLC

Organic modifier, pH, flow, temperature, gradient

 

Resolution, retention time, tailing, efficiency, detector response

 

HPTLC

Solvent composition, saturation, development distance, application/detection

 

Rf, resolution, densitometric response, band shape

 

  1. STATISTICAL MODELLING AND RESPONSE-SURFACE METHODOLOGY

 

For quantitative factors, a second-order polynomial is frequently used for response-surface modelling when justified by the selected design. The general form is:

Y = β? + Σβ?X? + Σβ??X?X? + Σβ??X?² + ε

Linear terms represent primary effects, interaction terms represent combined factor effects, and quadratic terms describe curvature. Model interpretation should consider statistical significance, model adequacy, residual behaviour, practical significance and experimental confirmation rather than relying on coefficient magnitude alone.

9.1 Model Evaluation

  1. ANOVA of the fitted model.
  2. Significance of relevant model terms.
  3. Coefficient of determination together with suitable adjusted/predicted measures.
  4. Lack-of-fit assessment where applicable.
  5. Residual plots and identification of unusual observations.
  6. Agreement between predicted and experimentally observed confirmation results.

9.2 Response-Surface Plots

Contour and three -dimensional response -surface plots can show how two factors jointly affect a response while another factor is held constant. Such plots are useful for visualizing regions that satisfy multiple criteria, but graphical interpretation should be supported by statistical evidence and confirmation experiments.

  1. METHOD VERIFICATION AND ANALYTICAL VALIDATION

Optimization and validation are distinct activities. Optimization de termines suitable analytical conditions, whereas validation establishes that the finalized procedure performs adequately for its intended purpose. Depending on the analytical application, important characteristics include specificity/selectivity, accuracy,  precision, linearity, range, detection limit, quantitation limit and robustness. System suitability is used to confirm system performance during analytical use.

 

TABLE 4. VALIDATION CHARACTERISTICS AND PURPOSE

Characteristic

 

Purpose

Specificity/selectivity

Demonstrate measurement of the intended analyte in the presence of relevant components

Accuracy

Assess closeness to an accepted/reference value

Precision

Assess agreement among repeated measurements

Response relationship/linearity

Demonstrate suitable relationship over the intended range

Range

Define interval over which required performance is demonstrated

LOD/LOQ

Characterize detection/quantitation capability when applicable

Robustness

Evaluate performance under deliberate small changes when appropriate

System suitability

Confirm system performance before/within analytical use

 

11. RELATIONSHIP WITH ICH Q14 AND ICH Q2(R2)

ICH Q14 provides a framework for science - and risk-based analytical procedure development and supports analytical  procedure lifecycle thinking. ICH Q2(R2) provides the framework for demonstrating that an analytical procedure is fit for its intended purpose. Chemometric optimization can connect these principles by translating the analytical objective into measurable r esponses, prioritizing factors through risk assessment, using DoE for structured experimentation, quantifying factor–response relationships through modelling, selecting an operating region, confirming predictions experimentally and then validating the final procedure.

 

TABLE 4. RELATIONSHIP TO CHEMOMETRIC OPTIMIZATIN

Development element

Chemometric contribution

 

Analytical objective/ATP responses

 

Defines target performance and analytical

Risk assessment

 

Prioritizes factors for experimental study

DoE

 

Provides structured experimentation

Model development

 

Quantifies factor–response relationships

Optimization

Identifies suitable operating conditions or     region

Confirmation

Tests model prediction experimentally

 

Validation                                                         Demonstrates fitness for intended purpose

Validation                                                         Demonstrates fitness for intended purpose

Lifecycle monitoring

Supports continued evaluation of analytical performance

 

 

 

 

  1. APPLICATIONS IN PHARMACEUTICAL QUALITY ASSURANCE
  1. Simultaneous estimation of multiple active pharmaceutical ingredients in combined
  2. dosage forms.
  3. Assay method development for single-component products.
  4. Stability-indicating chromatographic method development.
  5. Optimization of impurity and degradation-product separations.
  6. Quality control of tablets, capsules, creams, solutions and other pharmaceutical       formulations.
  7. HPTLC fingerprinting and quantitative densitometry where appropriate.
  8. Method robustness evaluation and analytical procedure transfer support.                    Development of efficient chromatographic procedures against predefined performance  targets.
    1. Why It Matters to Quality Assurance

A well-developed analytical procedure reduces the risk t hat analytical variability will obscure true product quality. Chemometric development can make relationships between method parameters and analytical performance more explicit, supporting rational control of critical variables and risk -based pharmaceutical quality systems.

  1. ADVANTAGES, LIMITATIONS AND PRACTICAL CHALLENGES
    1. Advantages
  1. Systematic rather than purely trial-and-error development.
  2. Simultaneous investigation of multiple variables.
  3. Ability to estimate interactions within the experimental region.
  4. Efficient use of experiments when designs are appropriately selected.
  5. Quantitative prediction of responses within a suitable model region.
  6. Facilitation of multi-response optimization.
  7. Support for risk-based and lifecycle-oriented analytical development.
    1. Limitations
  1. Requires appropriate statistical understanding.
  2. Incorrect factor selection can produce misleading optimization.
  3. Models are dependent on experimental region and underlying assumptions.
  4. Chromatographic peak integration and response measurement remain potential sources       of error.
  5. Optimization software cannot replace chromatographic expertise.
  6. Predicted optimum conditions require experimental confirmation.
  7. Validation remains necessary for the intended analytical application.
    1. Practical Challenges

The major practical challenge is translating chemical and chromatographic knowledge into suitable factors and measurable responses. A statistically sophisticated design cannot compensate for inappropriate stationary-phase selection, poor sample preparation, unsuitable detection conditions or unrealistic operating ranges. Chemometrics should therefore complement, rather than replace, chromatographic expertise.

 

 

FUTURE PERSPECTIVES

Analytical development is increasingly moving from traditional one-factor-at-a-time experimentation toward structured DoE, AQbD and data -driven optimization. Future developments may integrate automated experimentation, richer chromatographic datasets, multivariate modelling and machine -learning approaches. For HPTLC, DoE -supported optimization is likely to remain useful because several solvent and development variables can jointly affect migration and separation. The priority should not simply be increasing model complexity; it should be obtaining better analytical knowledge, improving robustness, reducing unnecessary experimentation and maintaining scientific interpretability.

CONCLUSION

Chemometric-assisted optimization provides a rational framework for HPLC and HPTLC method development by combining analytical knowledge, risk assessment, DoE, statistical modelling and multi-response optimization. HPLC development may investigate mobile-phase composition, pH, flow rate, temperature, gradient conditions and column chemistry, whereas HPTLC development may investigate solvent composition, chamber saturation, development distance, application and detection conditions. Published pharmaceutical examples demonstrate that DoE -supported optimization is a practical approach. Nevertheless, the predicted optimum should be experimentally confirmed and the finalized procedure appropriately validated. Integration with ICH Q14 and ICH Q2(R2) strengthens the connection between analytical method development, risk -based decision-making and analytical lifecycle management. The most effective implementation is therefore not simply the use of statistical software, but a scientifically justified sequence linking the analytical objective, critical factors, responses, model adequacy, confirmation and validation.

16. RESULTS AND DISCUSSION

The reviewed literature demonstrates that chemometric and DoE-based approaches can be integrated into pharmaceutical chromatographic development to study multiple method variables, quantify interactions and support multi-response optimization. The principal findings are summarized in the following tables and workflow.

17. AUTHOR DECLARATION

The author declares that this manuscript is a review article prepared through substantial restructuring, expansion and critical synthesis of an M.Pharm academic report and relevant scientific literature. The manuscript has not been previously published as a journal article and is not being considered simultaneously by another journal. The author has reviewed and approved the final manuscript. Any journal-specific requirements concerning prior academic-report or thesis-derived content will be disclosed to the target journal. The author declares no conflict of interest related to this manuscript.

18. CONFLICT OF INTEREST

The author declares that there is no conflict of interest associated with this review article.

19. FUNDING

No external funding was received for the preparation of this review article.

REFERENCES

  1. International Council for Harmonisation (ICH). ICH Q14: Analytical Procedure Development. Final Version. 2023.

 

  1. International Council for Harmonisation (ICH). ICH Q2(R2): Validation of Analytical Procedures. Final Version. 2023.
  2. Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J. An overview of experimental designs in HPLC method development and validation. Journal of Pharmaceutical and Biomedical Analysis. 2018;147:590–611. doi:10.1016/j.jpba.2017.05.006
  3. Patil SD, Chalikwar S. A brief review on application of design of experiment for the analysis of pharmaceuticals using HPLC. Annales Pharmaceutiques Françaises. 2024;82(2):203 –228. doi:10.1016/j.pharma.2023.12.011.
  4. Peng L, Li W, et al. Design of experiment techniques for the optimization of chromatographic analysis conditions: A review. Electrophoresis. 2022. doi:10.1002/elps.202200072.
  5. Hinge MA, Patel D. Optimization of HPLC method using central composite design for estimation of Torsemide and Eplerenone in tablet dosage form. Brazilian Journal of Pharmaceutical Sciences. 2022/2023. doi:10.1590/S2175-97902022e20219.
  6. Patel RB, Patel MR, Patni NR, Agrawal V. Efinaconazole: DoE -supported development and validation of a quantitative HPTLC method and its application for the assay of drugs in solution and microemulsion-based formulations. Analytical Methods. 2020. doi:10.1039/C9AY02599E.
  7. Patel RB, et al. Design, development and optimization of new high performance thin -layer chromatography method for quantitation of Retapam ulin in pharmaceutical formulation: Application of design of experiment. Separation Science Plus. 2020;3(4):121–128. doi:10.1002/sscp.201900107.
  8. Box-Behnken experimental design aided optimization of stability indicating HPTLC -based assay method: applica tion in pharmaceutical dosage form containing model drugs —Roxithromycin and Ambroxol Hydrochloride. Analytical Chemistry Letters. 2020;9(6):816 –834. doi:10.1080/22297928.2019.1700158.
  9. Elattar RH. Modern Optimization Strategies in High -Performance Liqui d Chromatography Analysis. Journal of Separation Science. 2026. doi:10.1002/jssc.70487.
  10. Massart DL, Vandeginste BGM, Buydens LMC, De Jong S, Lewi PJ, Smeyers -Verbeke J. Handbook of Chemometrics and Qualimetrics: Part A. Elsevier.
  11. Montgomery DC. Design and Analysis of Experiments. Wiley.
  12. Ermer J, Miller JH, editors. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. Wiley-VCH.
  13. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. Wiley.
  14. International Council for Harmonisation (ICH). ICH Q8(R2): Pharmaceutical Development.
  15. International Council for Harmonisation (ICH). ICH Q9: Quality Risk Management.
  16. International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System.
  17. International Council for Harmonisation (ICH). ICH Q12: Technical and Regulatory    
  18. Considerations for Pharmaceutical Product Lifecycle Management.
  19. United States Pharmacopeia –National Formulary. General Chapter <1225> Validation of    

Compendial Procedures.

United States Pharmacopeia–National Formulary. General Chapter <621

Chromatography.

  1. United States Food and Drug Administration. Analytical Procedures and Methods    

Validation for Drugs and Biologics: Guidance for Industry.

  1. United States Foo d and Drug Administration. Q14 Analytical Procedure Development.

Final Guidance for Industry. 2024.

  1.  United States Food and Drug Administration. Q2(R2) Validation of Analytical Procedures.

Final Guidance for Industry. 2024.

  1. European Medicines Agency. ICH Q14 Guideline on Analytical Procedure Development.

Step 5 – Revision 1. 2024.

  1. European Medicines Agency. ICH Q2(R2) Guideline on Validation of Analytical       

Procedures. Step 5 – Revision 1. 2024.

  1. Dejaegher B, Heyden YV. Experimental designs and their recent advances in analytical

chemistry: a review. Analytica Chimica Acta.

  1. Hibbert DB. Experimental design in chromatography: a tutorial review. Journal of

Chromatography B.

  1. Rozet E, Ceccato A, Hubert C, Ziemons E, Oprean R, Rudaz S, Boulange r B, Hubert P.

Analysis of recent pharmaceutical analytical methods using quality -by-design principles.    

Journal of Chromatography A.

  1. Reid GL, Morgado J, Barnett K, Harrington B, Wang J, Harwood JW, Fortin DT. Analytical    

method development and validatio n using quality by design principles. Journal of 

Pharmaceutical and Biomedical Analysis.

  1. Box GEP, Hunter JS, Hunter WG. Statistics for Experimenters: Design, Innovation, and

Discovery. Wiley.

  1. Ferreira SLC, Bruns RE, da Silva EGP, et al. Statistical designs and response surface
  2. techniques for the optimization of chromatographic systems. Journal of Chromatography       A. 2007;1158(1 –2):2–14. doi:10.1016/j.chroma.2007.03.051.

Reference

  1. International Council for Harmonisation (ICH). ICH Q14: Analytical Procedure Development. Final Version. 2023.

 

  1. International Council for Harmonisation (ICH). ICH Q2(R2): Validation of Analytical Procedures. Final Version. 2023.
  2. Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J. An overview of experimental designs in HPLC method development and validation. Journal of Pharmaceutical and Biomedical Analysis. 2018;147:590–611. doi:10.1016/j.jpba.2017.05.006
  3. Patil SD, Chalikwar S. A brief review on application of design of experiment for the analysis of pharmaceuticals using HPLC. Annales Pharmaceutiques Françaises. 2024;82(2):203 –228. doi:10.1016/j.pharma.2023.12.011.
  4. Peng L, Li W, et al. Design of experiment techniques for the optimization of chromatographic analysis conditions: A review. Electrophoresis. 2022. doi:10.1002/elps.202200072.
  5. Hinge MA, Patel D. Optimization of HPLC method using central composite design for estimation of Torsemide and Eplerenone in tablet dosage form. Brazilian Journal of Pharmaceutical Sciences. 2022/2023. doi:10.1590/S2175-97902022e20219.
  6. Patel RB, Patel MR, Patni NR, Agrawal V. Efinaconazole: DoE -supported development and validation of a quantitative HPTLC method and its application for the assay of drugs in solution and microemulsion-based formulations. Analytical Methods. 2020. doi:10.1039/C9AY02599E.
  7. Patel RB, et al. Design, development and optimization of new high performance thin -layer chromatography method for quantitation of Retapam ulin in pharmaceutical formulation: Application of design of experiment. Separation Science Plus. 2020;3(4):121–128. doi:10.1002/sscp.201900107.
  8. Box-Behnken experimental design aided optimization of stability indicating HPTLC -based assay method: applica tion in pharmaceutical dosage form containing model drugs —Roxithromycin and Ambroxol Hydrochloride. Analytical Chemistry Letters. 2020;9(6):816 –834. doi:10.1080/22297928.2019.1700158.
  9. Elattar RH. Modern Optimization Strategies in High -Performance Liqui d Chromatography Analysis. Journal of Separation Science. 2026. doi:10.1002/jssc.70487.
  10. Massart DL, Vandeginste BGM, Buydens LMC, De Jong S, Lewi PJ, Smeyers -Verbeke J. Handbook of Chemometrics and Qualimetrics: Part A. Elsevier.
  11. Montgomery DC. Design and Analysis of Experiments. Wiley.
  12. Ermer J, Miller JH, editors. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. Wiley-VCH.
  13. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. Wiley.
  14. International Council for Harmonisation (ICH). ICH Q8(R2): Pharmaceutical Development.
  15. International Council for Harmonisation (ICH). ICH Q9: Quality Risk Management.
  16. International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System.
  17. International Council for Harmonisation (ICH). ICH Q12: Technical and Regulatory    
  18. Considerations for Pharmaceutical Product Lifecycle Management.
  19. United States Pharmacopeia –National Formulary. General Chapter <1225> Validation of    

Compendial Procedures.

United States Pharmacopeia–National Formulary. General Chapter <621

Chromatography.

  1. United States Food and Drug Administration. Analytical Procedures and Methods    

Validation for Drugs and Biologics: Guidance for Industry.

  1. United States Foo d and Drug Administration. Q14 Analytical Procedure Development.

Final Guidance for Industry. 2024.

  1.  United States Food and Drug Administration. Q2(R2) Validation of Analytical Procedures.

Final Guidance for Industry. 2024.

  1. European Medicines Agency. ICH Q14 Guideline on Analytical Procedure Development.

Step 5 – Revision 1. 2024.

  1. European Medicines Agency. ICH Q2(R2) Guideline on Validation of Analytical       

Procedures. Step 5 – Revision 1. 2024.

  1. Dejaegher B, Heyden YV. Experimental designs and their recent advances in analytical

chemistry: a review. Analytica Chimica Acta.

  1. Hibbert DB. Experimental design in chromatography: a tutorial review. Journal of

Chromatography B.

  1. Rozet E, Ceccato A, Hubert C, Ziemons E, Oprean R, Rudaz S, Boulange r B, Hubert P.

Analysis of recent pharmaceutical analytical methods using quality -by-design principles.    

Journal of Chromatography A.

  1. Reid GL, Morgado J, Barnett K, Harrington B, Wang J, Harwood JW, Fortin DT. Analytical    

method development and validatio n using quality by design principles. Journal of 

Pharmaceutical and Biomedical Analysis.

  1. Box GEP, Hunter JS, Hunter WG. Statistics for Experimenters: Design, Innovation, and

Discovery. Wiley.

  1. Ferreira SLC, Bruns RE, da Silva EGP, et al. Statistical designs and response surface
  2. techniques for the optimization of chromatographic systems. Journal of Chromatography       A. 2007;1158(1 –2):2–14. doi:10.1016/j.chroma.2007.03.051.

Photo
Hemani Chauhan
Corresponding author

Department of Pharmaceutical Quality Assurance, Smt. S. M. Shah Pharmacy College, Mahemdabad, Gujarat, India.

Photo
Shivani jani
Co-author

Department of Pharmaceutical Quality Assurance, Smt. S. M. Shah Pharmacy College, Mahemdavad, Gujarat, India.

Photo
Dr. Pinak Patel
Co-author

Smt. S. M. Shah Pharmacy College, Ahmedabad–Mahemdabad Highway, Bhumapura, Mahemdabad, Kheda-387130, Gujarat, India

Photo
Dr. Krunal Detholia
Co-author

Smt. S. M. Shah Pharmacy College, Ahmedabad–Mahemdabad Highway, Bhumapura, Mahemdabad, Kheda-387130, Gujarat, India

Hemani Chauhan, Shivani Jani, Dr. Pinak Patel, Dr. Krunal Detholia, Chemometric-Assisted Optimization of HPLC and HPTLC Methods In Pharmaceutical Quality Assurance, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 10, 1050-1061, https://doi.org/10.5281/zenodo.23210721

More related articles
Formulation And Evaluation of Herbal Lip Scrub...
Alok Giri, Kale Pramod, Dnyaneshwar Mhetre...
Transforming Pharmaceutical Manufacturing for Plan...
Pooja Kedar, Priyanka Supare, Janhavi Patil, Prem Shinde, Vaibhav...
Organoids as Living Drug Testbeds: Emerging Technologies and Precision Pharmacol...
Balakoti Erothi, Donka Devi, K Eswar Kumar, Routhu Pratyusha, Mahankali Manichandana, Tagore Tanniru...
More related articles
Formulation And Evaluation of Herbal Lip Scrub...
Alok Giri, Kale Pramod, Dnyaneshwar Mhetre...
Transforming Pharmaceutical Manufacturing for Planetary Health: A Review on Gree...
Pooja Kedar, Priyanka Supare, Janhavi Patil, Prem Shinde, Vaibhav Ghongate, Kuldipak Parkhe...
Formulation And Evaluation of Herbal Lip Scrub...
Alok Giri, Kale Pramod, Dnyaneshwar Mhetre...
Transforming Pharmaceutical Manufacturing for Planetary Health: A Review on Gree...
Pooja Kedar, Priyanka Supare, Janhavi Patil, Prem Shinde, Vaibhav Ghongate, Kuldipak Parkhe...